Bortezomib (Intravenous Route, Subcutaneous Route)Drug Information provided by: Micromedex
US Brand Names
Bortezomib injection is given together with melphalan and prednisone to treat multiple myeloma (blood plasma cell cancer) in patients with or without a prior history of treatment, and mantle cell lymphoma in patients who have received at least one treatment and did not worked well.
Bortezomib interferes with the growth of cancer cells, which are then eventually destroyed by the body. Since the growth of normal body cells may also be affected by bortezomib, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, such as a skin rash, may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.
This medicine is to be administered only by or under the supervision of your doctor.
This product is available in the following dosage forms:
- Powder for Solution